Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COVID-19 Cash Crisis Leaves UK Research Charities On The Cusp

Could Lose A Generation Of Scientists

Executive Summary

Over 150 medical charities including the British Heart Foundation and Cancer Research UK are forecasting a 41% decrease in their research budgets over the next year and are demanding £310m in 2020/21 from the UK government as part of a matched funding program.

You may also be interested in...



Coronavirus Update: BMS Expands Medicine Program, Cancer Research UK Cuts Funding

Bristol-Myers Squibb is to give away more medicines to uninsured US patients, Cancer Research UK tells of funding hardship, Oxford Biomedica joins a consortium to rapidly develop a vaccine, while a Korean company works on a stem cell therapy.

Changing Of The Guard At Merck KGaA With Garijo Succeeding Oschmann As CEO

The appointment of Belén Garijo as CEO of the German major from May next year is a small but significant step on the road to addressing gender inequality at the very top level of management in the world of big pharma.

Shaking Off US Rebuff, Gilead And Galapagos Get Filgotinib Green Lights In EU And Japan

Galapagos and Gilead's JAK inhibitor has been approved for rheumatoid arthritis in the second and third biggest pharma markets, softening the blow somewhat of rejection from the US FDA in the biggest market last month.

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel